Carr Roxane R, Nahata Milap C
College of Pharmacy, Ohio State University, Columbus, OH 43210-1291, USA.
Ann Pharmacother. 2004 Sep;38(9):1520-4. doi: 10.1345/aph.1D589. Epub 2004 Jun 22.
To review the literature concerning the use of azithromycin in the treatment of patients with cystic fibrosis (CF).
A search of MEDLINE (1966-April 2004), Embase (1980-April 2004), and International Pharmaceutical Abstracts (1971-April 2004) was performed. Search terms included cystic fibrosis, macrolide, and azithromycin.
Four studies have been performed in 7-185 patients (children and adults) over a 3- to 6-month period. The azithromycin dosage ranged from 250 mg 3 times weekly to 500 mg daily. The trials reported an improvement in percent predicted forced expiratory volume ranging from 2.95% to 6.2% in patients treated with azithromycin compared with those receiving placebo.
Azithromycin appeared to improve pulmonary function in adults and older children with CF and was well tolerated when administered for 6 months. Further research is needed to determine an optimal dosage regimen, duration of treatment, effects on quality of life, and cost-effectiveness of azithromycin therapy.
回顾有关阿奇霉素用于治疗囊性纤维化（CF）患者的文献。
检索了MEDLINE（1966年至2004年4月）、Embase（1980年至2004年4月）和国际药学文摘（1971年至2004年4月）。检索词包括囊性纤维化、大环内酯类和阿奇霉素。
在3至6个月期间，对7至185名患者（儿童和成人）进行了四项研究。阿奇霉素的剂量范围为每周3次250毫克至每日500毫克。试验报告称，与接受安慰剂的患者相比，接受阿奇霉素治疗的患者预计用力呼气量百分比提高了2.95%至6.2%。
阿奇霉素似乎能改善成年和大龄CF儿童的肺功能，且在给药6个月时耐受性良好。需要进一步研究来确定阿奇霉素治疗的最佳剂量方案、治疗持续时间、对生活质量的影响以及成本效益。
